InnoCare Pharma
20241231
2024123120231231
20242023
1,009,448738,537(138,441)(128,435)871,007610,102210,828244,153(419,961)(366,891)(814,027)(751,176)(183,860)(193,520)
(46,428)(92,674)(452,856)(645,632)
(430,800)(490,668)
20241231
20231231
*7,762,9118,287,136*
20231231670.7
49.1%202412311,000.4MZL
20231231
738.536.7%202412311,009.4
20231231610.142.8%20241231871.020241231
86.3%2023123182.6%3.7
202312311,311.68.1%20241231
1,417.8(i)20231231366.914.5%20241231
420.0
202354.6%202441.8%
(ii)20231231751.2
62.820241231814.0(iii)20231231193.5
5.0%20241231183.9
20231231645.629.9%20241231452.9
2024123178
20242023
(452,856)(645,632)32,84889,861(10,792)65,103(430,800)(490,668)
2025BLAICP-248 (mesutoclax)20251L
CLL/SLLIIIICP-248
NHL
20241231
?BTK20241231
1,000.4102023670.7
49.1%
CLL/SLL
MCLMZLNRDL MZLBTK
MZLBNHL2023DOI10.1002/ajh.27058
CSCO2024MZL
DOT 1L CLL/SLL
NDA20248CDE
MCLII
TGANDA
ICP-B04CD19(Minjuvi
?) 20246BLA
NMPACDEASCTDLBCLDLBCL
2025BLAIIDLBCL
IRCORRDCRDoRPFSTTPTTROS
EHA20242024129IRCORR73.1%32.7%
CR40.4%PRORR
69.2%34.6%CR34.6%PR
BLAASCTDLBCLDLBCL
ASCTDLBCLDLBCL
CSCOASCTDLBCL
ICP-248 (Mesutoclax)
ICP-248B2BCL-2
42CLL/SLLTN CLL/SLLICP-248TLS
5.5
ORRCRRuMRD100%53.4%
46.2%MRD12
20252CDEICP-248CLL/SLLIII202531L CLL/SLL ICP-248I/IICLL/SLLMCLNHL
PKICP-248BCL-262
16CLL/SLL24MCL125mg ICP-248
CLL/SLLORR87.5%CRR
6.3%MCLORR79.2%CRR37.5%17BTKORR70.5%CRR23.5%10BTKCLLORR80.0%CRR10.0%20253CDEBBTKi
MCLICP-248II
NHL ICP-248
AMLICP-B02 (CM355) ICP-B02CD20CD3I/II
ICP-B02NHLPK
IVSC
IVSCICP-B02FLDLBCL 20251
02162
50%Prolium Bioscience Inc.ProliumICP-B02
50%1,750
5.025
Prolium
ICP-490
ICP-490
NHLI/II20239INDCDEICP-490
ICP-490≥1.0mgICP-490
PDAiolos (IKZF3)Ikaros (IKZF1)ICP-490NHLFPI20253ICP-490
NHL
ICP-B05 (CM369) ICP-B05CC8CCR8
( 2162.HK )IICP-B05NHL
NHLICP-B05450600ICP-B05
DLT3AEPKT20251612124(33.3%)PR6PFS82.5% (95% CI46.1%-95.3%)CCR8+10%5
4(80%)PR
ICP-B05
BT
3.7%
20291,850
2023103iHealthcareAnalyst, Inc.BT
20249FDA
PPMSIIIFDASPMSPMSIII20252FDASPMSIII
PPMSSPMSIII2025PPMS2025SPMS
MS
ITP
PoCIII2025III2026NDA2023612ITPII
EHA 202320244(The American Journal of Hematology)50QD40%GC
IVIG75% (6/8)BTKITP
SLEIIaSLE
SRI-4
SLEIIb20242025
ICP-332 (Soficitinib) ICP-3322TYK2
T20243ICP-332
ADII2024AAD
ICP-3324
EASI8078.2%(p<0.0001)12072.5% (p<0.0001)
16.7%ICP-33280120
EASI 50EASI 75EASI 9050%75%90%IGA0/18012064%EASI 758%(p<0.0001)TRAE
2024AD III
110II/IIIIND
ICP-332IFDA
ICP-488 ICP-488TYK2TYK2
JH2IL-23IL12IIFN
ICP-488202410ICP-488II
II2025
QD69ICP-48812
PASI75%PASI 75ICP-488PASI 90PASI 100
sPGA0/1 12ICP-488PASI 7569
77.3%78.6%(11.6%p<0.0001)
12ICP-488PASI 9069
36.4%50.0%(0%p<0.05)PASI 100
6911.4%11.9%(0%p<0.05)
12sPGA 0/16970.5%71.4%
(9.3%p<0.0001)sPGA 10
TEAE
IIIICP-488
ICP-48820253
IIIFPI
IL-17 IL-17-17
IL-17
IL-17AAIL-17AFIL-17R
IL-17
(CIA)IL-17
IL-17
ADC
ADCICP-723
ICP-723 (Zurletrectinib) ICP-723TRK
TRKTRKNTRKNTRK12ICP-723 IIIRCORR
ISE55IRCORR85.5% (95%CI73.3,93.5)ZurletrectinibTRK
TRKiICP-723NDA2025
2025NDAICP-189 ICP-189SHP2
IaICP-189
160QD120DLT3TRAEICP-189PK120ICP-189DUSP6IC
DUSP6MAPKICP-189201PR142023714ArriVent BiopharmaArriVent
SHP2ICP-189ArriVentfirmonertinibEGFR
NSCLCICP-189firmonertinibEGFRICP-189firmonertinibIb
DLTSMCICP-189160firmonertinib 8098
2ICP-189 160firmonertinib 80
2025Ib
(ADC) ADC—LP
ADC
— ADC DAR8
ADC
ADC
ICP-B794B7H3ADC ICP-B794ADCB7H3
8ICP-B794—
—
ICP-B794SCLCNSCLCCDX
NCI-H1155 NSCLC CDX
0.3mg/kg ICP-B794100%TGI— B7H3700mm
5mg/kg ICP-B794
NCI-H1155
2002025ICP-B794IND
2.0
MZL2025
2.020251ProliumICP-B02
2025
2025
2.0
2025
2025
ProliumICP-B02CD20XCD3
2025BLAICP-248(mesutoclax)20251L CLL/SLL
IIIICP-248
NHL
BT
B
20249FDAPPMSIIISPMSIII
ITPPoCGC/IVIG2023III
20252026NDASLEIIaSLEBTKIIb202410
186482025
TICP-332ICP-488III
ADPNSLEIBD
IL-17
ADC
ADCICP-723NDA
ADCICP-B794B7H3ADC
2025ICP-B794IND2025
ADC
ADC—
ADC
IND
AI
AIAI
AIAI
ADC
Socitinib(ICP-332)TYK2/JAK1
Prurigonodularis(Global)
ICP-189+EGFRiSHP2
NSCLC(CHN)
ICP-B02CD3XCD20NHL(CHN)ICP-490E3 LigaseMM(CHN)NHL(CHN)ICP-B05CCR8
Hemato-oncology(CHN)SolidTumor(CHN)
OrelabrutinibBTKTNMCL (CHN)MZLconrmatory(CHN)ITP(CHN)SLE(CHN)2b
PPMS(Global)SPMS(Global)
TafasitimabCD19
DLBCL(CHN)
Mesutoclax+Orelabrutinib
BCL2
TNCLL/SLL(CHN)
Socitinib(ICP-332)TYK2/JAK1AtopicDermatitis(CHN)Vitiligo (CHN)
ICP-488TYK-2
Psoriasis(CHN)
OrelabrutinibBTK
TNCLL/SLL(CHN)r/rMZL(SG)r/rMCL (AU)
TafasitimabCD19
r/rDLBCL(MainlandCHN)
ZurletrectinibNTRK
NTRKfusion-positivecancers(CHN)
OrelabrutinibBTK
r/rCLL/SLL(CHN)r/rMCL (CHN)r/rMCL (SG)r/rMZL(CHN)
TafasitimabCD19
r/rDLBCL(GBA)r/rDLBCL(HK)r/rDLBCL(Macao)r/rDLBCL(TW)
ADC
Solidtumor
IL17
Autoimmunedisease
OthersAutoimmunedisease
Mesutoclax(ICP-248)BCL2
r/rNHL(CN)AML(CN,AU)
?
BTK?BTK2022CLL/SLLMCL2024
MZL2023
?
CSCOCLL/SLLMCLBTK
BDLBCLpCNSL
202412311,009.4202412311,000.41020231231
49.1%330
(i)(ii)MZLBTK(iii)(iv)DOT
2025BLAICP-248(mesutoclax)20251L CLL/SLL
IIIICP-248
NHL
1,300CLL/SLLMCL
MZLMZLBTK
MZLMZLBNHL
8.3%MZL
MZL20234NMPAMZL
MZLBTK2023616ICML
MZLIRC2014ORR
IV75.9%
24.3IRCORR58.9%DoR34.3
12PFS82.8%OS91%TRAE12
IIIR2R2MZL
ASH 2023(Jiadai Xu, Lu-Ya Cheng, Yang Ke, et al. Blood 2023142 (Supplement 1)6146.)MZLMZL103(30%)CR6(60%)PRORR90%13.07.8
24.7PFS6PFS100%
OS2023568
9.63.017.8ORR75%(6/8)11
1L CLL/SLL
IIICLL/SLLIRCPFS1L CLL/SLLIII2024NDA
1L MCLMCLIII
CLL/SLL
IICLL/SLL15080CLL/SLL202362652.4
42.5%ORR93.8%CR30%
1.84DORPFS5250
CLL/SLLBTKCR
AE
MCLMCLBB
MCL60
MCL
CR
202352BloodBlood AdvancesASHMCL
MCL
10620236946.98
CTORR83%
35.8%3.8%CRu43.4%PR
DoR25.79PFS24.94OS
56.21
(OLR)MCLII(Huilai Zhang,Liping Su, LihongLiu, et al. Blood 2023142 (Supplement 1)736.)21(75.0%)616(76.2%)CR5(23.8%)PR100%2118MRD18MRDPB-MRDMRDBM-MRD
DoRPFS12DoRPFS90.9%
92.3%
pCNSLEHA 2023
pCNSLII
pCNSLND pCNSL
ORRpCNSLpCNSL
2022ND pCNSLCNSLND pCNSLORR88.9%100%CR53.9%61.8%ND pCNSL
PFSmPFS6PFS63.6%100%
60%CNSLORR60%
86.7%mPFS9.83
mPFSBCRMYD88
MOA
BBBBBB15021.6BBB58.6%
pCNSL
ICP-248BCL-2
BTKBCLL/SLL
CLL
CLLBTKPFSBTKOSBTK
BCL-2BCL-2B
BCL-2BTKCLL/SLLMCL
CLL/SLL
ICP-248BCL-2CLL/SLL
ICP-B04 ()
IIASCTDLBCLBLA20246NMPACDE
2025NDAIIDLBCLIRCORRDCRDoRPFSTTPTTROSEHA 20242024129IRCORR73.1%32.7%CR40.4%
PRORR69.2%34.6%CR34.6%PR
ASCTDLBCLDLBCLDLBCLB-NHLCD19B-NHLCSCOASCTDLBCL
BLAASCTDLBCL
DLBCL
ICP-248 (Mesutoclax)ICP-248BCL-2BCL-2
BCL-2ICP-248ICP-248DDIBLC-2
ICP-248BCL-2
ICP-248CLL/SLLNHL42TN CLL/SLLICP-248
II
5.5 ORRCRRuMRD100%53.4%46.2%MRD1220252CDEICP-248CLL/SLLIII20253
1L CLL/SLLICP-248I/IICLL/SLLMCL
ICP-248BCL-26216CLL/SLL24MCL125mgICP-248CLL/SLLORR87.5%CRR
6.3%MCLORR79.2%CRR37.5%17BTK
ORR70.5%CRR23.5%10BTKCLLORR80.0%CRR10.0%20253CDEBBTKiMCLICP-248II
NHL
ICP-248AML
ICP-B02 (CM355)ICP-B02B
CD20CD3
TTDCC
ICP-B02 IVSCIVSCFLDLBCL
0.5/1.5/6
ICP-B02BICP-B02SCIVNHLI/IIB
CRCD19CD20BBB
ICP-B02
2025102162
50%ProliumICP-B02
ProliumICP-B02
ICP-B02 50%
50%1,750
5.025
Prolium
2025120ICP-490ICP-490CereblonCRBNE3
IMiDTPD
CRL4
CRBN
E3ICP-490IKZF1IkarosIKZF3Aiolos
ICP-490DLBCL
ICP-490CRBNICP-490
ADCCCD38daratumumab
20234182023AACRICP-490
ICP-490NHLDLBCL
IC
ICP-490ICP-490ICP-490
DLBCLICP-490mAb
ICP-490IL-2BCD38daratumumab
NHLICP-490BTK
NHLI/II20239INDCDEICP-490
ICP-490≥1.0mgICP-490
Aiolos (IKZF3)Ikaros (IKZF1)ICP-490NHL20253ICP-490
NHLICP-B05 (CM369)ICP-B05C-C8CCR8
CCR8TMETTregsICP-B05CCR8TregsADCC
TregsTMEICP-B05
TregsTregs
TregsICP-B05
IICP-B05NHLNHLICP-B05450600ICP-B05DLT3TRAEPK
T2025161212433.3%PR6PFS82.5%95%CI46.1%-95.3%CCR8+10%5480%PR
ICP-B05
BT
3.7%20291,850
2023103iHealthcareAnalyst, Inc.BT
?侜?唝廘岭
SLE:
AD:
PN:
PPMS:
SPMS:
ITP:
CNSB
20249FDAPPMSIIISPMSIII20252FDASPMSIII
PPMSSPMSIII2025PPMS2025SPMS
ITPPoCGC/IVIG
III20252026NDASLEIIa
SLEBTKIIb20241018648
2025CSUHS
TTYK2ICP-332ICP-488TADPNSLELNCDUC
BICP-332ICP-488T
B—
BTKTECB
BCRBBTKBTK
MS20249FDAPPMSIIIFDASPMSPMSIII
20252FDASPMSIII
PPMSSPMSIII2025PPMS2025SPMS
RRMSIIACTRIMSMS2025227P094
IIIII1581:1:1:150
8050
135012Gd+T14812Gd+T1
12Gd+T1
T2(p<0.05)80
502450
(p<0.05)801290.4%245092.3%
50QD
24Gd+T1 (PHS , N=115)
QD=BID=CI=Gd+ =
50QD50QD50BID80QD
6.45 (3.62, 11.52)2.10 (0.62, 7.11)1.08 (0.30, 3.81)0.50 (0.09, 2.74)
67.4 (-22.0, 91.3)83.3 (33.2, 95.8)92.3 (56.5, 98.6)
0.09580.01140.0037ITPITP
ITP
T
ITP100,00023.6100,0009.5
CD20
BTKBITPB
BTKITPITP
2023ITPII
IIITPIII
5010
/L742023263350QD30QD
ITP50QD
GC/IVIG36.4%33125040%1561283.3%121014246450x10
/L22GCIVIG5075.0%86ITPTRAE12
IIITPPoC
BTKITPBTK2023612EHA 2023ITPIIPoC20244(The American Journal of Hematology)2023III2025
2026NDA
SLEBTKBCRBSLE
SLE
2025SLE1.0620202025
0.7%2030SLE1.09202520300.5%
SLEIIa
SLE1:1:1:112
5080100IIa
508010012SRI-4
35.7%50.0%61.5%64.3%
GC3C4IIa
2022EULAR
5080100
SRI-4 12
N=55
IIaIIb
IIbSLESLE
1:1:1507548SRI-4C3C4dsNDAIIb
2024104850%CDEIIb2025
IIaSLEBTK
SLE
T— TYK2ICP-332ICP-332TYK2TYK2JAKIL-12/IL-23
IFN
T17TH17TH1B
IBDADICP-332TYK2
400JAK2JAK
TYK2ICP-332ADIBD
PharmaIntelligenceAD12
0.96-22.6%1.2-17.1%2030100
Frost & SullivanAD201965.7203081.71.7%J Allergy ClinImmunol Pract. 2021 Apr9(4)1488–1500AD
33%90%
AD
ICP-332
202312IIPoCII
ICP-332AD75AD80mg QD120mg QD2528
ICP-3324ADICP-33280120
EASI 50EASI 75EASI 90EASI≥50%75%90%(IGA)0/1
-
-
20%
8%0%10%20%30%40%50%60%70%80%
EASI50EASI75
72%*
64%*64%*90%
88%*EASIEASI
4EASI 50EASI 75
ICP-33280QD
ICP-332120QD
ICP-332 80ICP-332 120(EASI)(+/- SE)(%)
ICP-332 80ICP-332 120*p<0.0001*p<0.0001
-16.7%
-80%-70%-60%-50%-40%-30%-20%-10%
0%
-78.2%*
-72.5%*
p<0.0001
ICP-
(DLQI)
p<0.01
(N=25)
ICP-33280
(N=25)
ICP-332120(N=25)
D8/W1-3.3(-4.8,-1.9)-6.5(-8.0,-5.1)-6.8(-8.4,-5.3)
ppp
0.00270.0018
D15/W2-2.2(-4.2,-0.2)-8.7(-10.7,-6.7)-7.9(-9.9,-5.9)
<0.00010.0002D29/W4-1.2(-3.3,0.9)-10.8(-12.8,-8.8)-8.9(-11.0,-6.8)
<0.0001<0.0001ICP-332 80ICP-332 120
80120EASI
78.2%72.5%16.7%(p<0.0001)80120EASI 7564%64%
EASI 758%(p<0.0001)80EASI 7556%EASI 9040%IGA 0/132%NRS≥456%(p<0.01)
NRS (p<0.01)80120ICP-3322(p<0.01)ICP-332AD
TRAETRAEII2024ICP-332 IIAD
ADICP-332ADIII2024AD III
ICP-332ICP-332IFDAICP-488ICP-488TYK2JH2JH2TYK2
JH2TYK2ICP-488
TYK2TYK2 JH2IL-23IL-121IFNICP-488SLELNIBDICP-488ICP-332TYK2
T23(IL-23)T17(Th17)
2022
1.252%3%
ICP-488II
ICP-488PASI 90PASI 1000/1
12PASI 75(FAS)
12ICP-488PASI 7577.3%78.6%69
(11.6%p<0.0001)
12ICP-488PASI 9036.4%50.0%69(0%p<0.05)PASI 100
11.4%11.9%69(0%p<0.05)
12sPGA 0/170.5%71.4%69(9.3%p<0.0001)sPGA 10
TEAETRAEII2025
IIIFPI2025
ADC
ADCICP-723
ICP-723 (Zurletrectinib)ICP-723TRKTRKNTRK
TRKTRK
ICP-723TRKA/B/CTRKAG595RG667CICP-723TRK20247(British Journal of Cancer)(Nature)zurletrectinibzurletrectinib
TRK
zurletrectinibTRKATRKBTRKCTRKA G595RTRKA G667C
ZurletrectinibselitrectinibrepotrectinibTRKA G598R/G670A
zurletrectinib(15 mg/kg)NTRKTRKselitrectinibrepotrectinibzurletrectinib41.566.5104P < 0.05
repotrectinib(15 mg/kg)selitrectinib(30 mg/kg)P=0.0384
0.0022
TRKTRKATRKBTRKC
NTRK1NTRK2NTRK3TRKNTRKNTRKNTRK
NTRK12ICP-723 IIIRCORRISE55IRCORR85.5% (95% CI: 73.3, 93.5)ZurletrectinibTRKTRKi
ICP-723NDA202532122025NDAICP-189ICP-189SHP2ICP-189SHP2RAS-MAPK
PD-1SHP2
ICP-189ICP-189EGFRKRASMEKPD-1
ICP-189ICP-189p-ERKDUSP6 mRNA
IaICP-189
QD120DLT3
TRAEICP-189ICP-189DUSP6IC
DUSP6MAPKICP-18920
1PR14
2023714ArriVent
SHP2ICP-189ArriVentfirmonertinib
EGFRNSCLCICP-189firmonertinibEGFRICP-189firmonertinibIbDLTSMCICP-189 160firmonertinib 80982ICP-189 160firmonertinib 80
22025Ib
(ADC)
(ADC)
ADC
ADC—(LP)
ADC ADC (DAR)8
ADCICP-B794B7H3ADCICP-B794ADCB7H3
8ICP-B794—
—
ICP-B794SCLCNSCLCCDXB7H3B7B7H3B7H3
ICP-B794NCI-H1155 NSCLC CDX0.3mg/kg ICP-B794
100%TGI—
B7H3
ICP-B794NCI-H1155
XenograftCDXmodel(NSCLC)
ADC100200 mm
ICP-B794
CDXNSCLC
1IVIV3IV2IV
n=8n=8n=8n=8
700 mm
5 mg/kg ICP-B794NCI-H1155
ADC
MTD
MED 0.15 mg/kg200ADC2025ICP-B794IND
83,000
GMPNMPABTK
20228
2022
PPQ202519,600
CMC70,381
202442620232023ESG
ESG2023ESG2028
202310%100%
202412,337,750202420241217
20241231
2025121
13.51(2)
2025121
2025193.09D
202512220251241,126,000
5.825.57
6,421,700
20241231
123120242023
%%
1,005,62199.6671,58290.93,8270.466,9559.1
1,009,448100.0738,537100.0
20231231738.5202412311,009.420231231
671.649.7%202412311,005.62023
49.1%2023
123120242023
%%
868,72799.7581,11495.22,2800.328,9884.8
871,007100.0610,102100.0
20231231610.142.8%20241231871.020241231
86.3%2023123182.6%3.7
20231231244.220241231210.82023123138.217.12024123121.120231231
192.320.720241231
171.6
20231231366.920241231420.0
202354.6%202441.8%
123120242023
%%224,96953.6171,82946.8186,93544.5155,11542.3(29,745)(7.1)8,2232.2
37,8029.031,7248.7
419,961100.0366,891100.0
20231231751.28.4%20241231814.0
123120242023
%%
333,26640.9291,71238.8282,89134.8255,43634.0(3,097)(0.4)29,0453.976,7569.459,9978.0124,21115.3114,98615.3
814,027100.0751,176100.0
(i) 291.741.6
333.3
(ii) 255.427.5282.9
(iii) 29.032.1-3.1
(iv) 60.016.876.8
(v) 115.0
9.2124.2
20231231193.59.620241231183.92023
123120242023
%%
81,87144.579,90441.322,05012.027,83614.425,88614.131,55316.316,8319.216,7378.615,2368.39,7045.0BTK
——10,7665.621,98611.917,0208.8
183,860100.0193,520100.0
2023123192.72024123146.4
20231231
54.02024123129.620248
202412315.3202312314.9
2023123135.12024123133.8
123120242023
351,002307,638
88,084113,99495,577119,0951,062,899—6,222,6268,224,596
7,820,1888,765,323
193,7975,000128,363134,905695,512667,71711,72412,00831,60823,233
—1,251,131
1,061,0042,093,994
6,759,1846,671,329
202412316,759.2
6,222.6
351.01,062.9
695.5128.4
193.8
123120242023345,906248,9425,09658,696
351,002307,638
2021
20231231114.02024123188.1(i)2023123162.544.32024123118.2(ii)20231231
39.018.32024123157.3
12312024202357,29139,04418,19962,54010,63110,3901,9632,020
88,084113,994
20231231119.12024123195.6
123120242023762,907—759,179—
1,522,086—
1,062,899—459,187—
1,522,086—
202412311,062.9459.220231231
123120242023111,795124,20713,45710,432
2,99019912167
128,363134,905
20231231667.720241231695.5(i)2023123153.02024123162.6(ii)2023123115.32024123131.1(iii)2023123158.220241231
47.8
12312024202347,84858,19062,64952,99931,11315,25319,50411,85339,83738,336476,336476,33618,22514,750
695,512667,717
123120242023
193,7975,00031,60823,233476,336476,336
—1,251,131
1,018,70026,300
27,44043,647303,134305,577
2,051,0152,131,224
202312312,131.2202412312,051.0
20231231
280.920241231263.0
20231231759.820241231784.3
20231231293.820241231
281.8
2023123139.02024123135.9
202312315.7202412310.4
2023123152.42024123122.6
123120242023
7.44.2
20203238.95250,324,0000.0000023,883
2,240.4
2020323H.10
2020415
37,548,00015%
322.59
2021210210,508,00014.45
2021232021210
2022921264,648,2170.000002
11.03
2,778.82
202412317,762.9202312318,287.1
14.075%
20241231
(i)3.3(ii)
0.920241231760
15.620241231
20241231
20241231
20241231
100%21.2%20231231
20.8%
202412311,212.5193.8
303.1476.3
727.520241231377.2
20241231
20241231
20241231
20241231202412312023
2025620
20256172025620
2025616
183171712-1716
201511320203232022921
— 2024925
2024925—
20249252024925— 2025121
2025121
13.51B(1)
C.2.1
(i)(ii)
(iii)
C3
20241231
20241231
202398200
2,198,00011,301,21020241231548,0001,650,0002024272024829
20232024
202462710%2024427
2024560,0003,340,55020241231560,000
20241548,00065.63,162,780202421,650,0005.134.548,138,430202412560,0006.125.863,340,550
2,758,0006.124.5414,641,760
(1)
(2)(3)
20241231
20241231
3.10(2)3.21
20241231
2,415.67
202412311,583.0
65.5%
2024
20241231
50%
1,207,835261,55051,576209,974
2026
40%
966,268633,19716,513616,684
2026
10%
241,56721,30015,2856,015
2026
2,415,670916,04783,374832,673
2024111120212202122
Gaoling Fund L.P.YHG Investment L.P.Vivo
210,508,000
16.33%
14.04%
14.45421.023,041.44210,508,000
14.4520212215.72
3,041.843,041.442021210
20241231
20231231
2024
20241231
(i)
IND
241,975
4,093
2027
(ii)
638,44940,737
(iii)
273,193529(iv)
722,28154,716
3,041,4401,875,8981,165,542100,0751,065,467
1. 202122
2.
20241111
20229212,919.07
140.25
2,778.82
20229162022916
20241231
2024
202412
1,494,220.61,242,867.3157,240.61,085,626.72027
116,146.625,878.13,988.021,890.12027
273,851.4159,144.746,121.3113,023.42027
60,952.332,296.13,436.628,859.52027
833,644.7364,916.3263,737.7101,178.62027
2,778,815.61,825,102.5474,524.21,350,578.3
20253
2024123120241231
20242023
1,009,448738,537
(138,441)(128,435)
871,007610,102
210,828244,153(419,961)(366,891)(814,027)(751,176)(183,860)(193,520)
(46,428)(92,674)
(29,609)(53,963)
(1,495)(268)(5,260)(4,900)
(33,788)(35,069)
(452,593)(644,206)
(263)(1,426)
(452,856)(645,632)
(440,633)(631,263)
(12,223)(14,369)
(452,856)(645,632)
0.260.37
20241231
20242023
(452,856)(645,632)
60,761113,544
60,761113,544
(392,095)(532,088)
(379,872)(517,719)
(12,223)(14,369)
(392,095)(532,088)
20241231
20241231
20231231
784,328759,764281,758293,8373,1253,12535,91839,0074005,660
— 459,187—22,59052,413
1,587,3061,153,806
95,577119,095
351,002307,638
88,084113,994
— 1,062,899—6,222,6268,224,596
7,820,1888,765,323
128,363134,905695,512667,71711,72412,008193,7975,00031,60823,233—1,251,131
1,061,0042,093,994
6,759,1846,671,329
8,346,4907,825,135
20241231
20231231
1,018,70026,30027,44043,647303,134305,577251,281268,906
1,600,555644,430
6,745,9357,180,705
2323(3,097)—6,728,3757,147,825
6,725,3017,147,848
20,63432,857
6,745,9357,180,705
1.
2015113Ogier Global (Cayman)Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, CaymanIslands
20203232022921
1100.00%—
—
100.00%
InnoCare Pharma Inc. 3—
100.00%
InnoCare Pharma Australia Pty Ltd.10—
100.00%
(a)
80,000,000—
100.00%
(b)
10,000,000—
100.00%
(b)
66,474,400—
93.39%
(b)
4,000,000—
100.00%
(b)
1,000,000,000—
93.00%
(b)
2,000,000—
100.00%
(a)(b)
2.1
20241231
(a)(b)(c)
2.2
2020
2022
(a) 16—
—
(b) 2020
2022
2023202411
(c) 77
2.3
—
202511
202611
202711
3334
202711
102810
1028
—
B38
IG1IG14IG20B
3.3.3
95.1.39A
10B74
10B73
3.
(a)
202420231,005,209673,1344,23965,403
1,009,448738,537
(b)
202420231,117,9091,153,3921,791414
1,119,7001,153,806
10%
20242023A421,998249,438B134,820111,890C*93,421
556,818454,749
* 20241231C10%
4.
202420231,009,448738,537
(a)
20242023
1,005,621671,5822,02359,758
—5,6451,8041,552
1,009,448738,537
1,005,209673,134
4,23965,403
1,009,448738,537
1,007,425678,779
2,02359,758
1,009,448738,537
20242023
—17,783
(b)
3090
20242023
21,05738,212171,589192,33312,37610,4725,8063,136
210,828244,153
5.
16.5%2023
16.5%
2,000,00020232,000,0008.25%20238.25%
16.5%202316. 5%
25%15%202415%202315%15%
15%
2024202312315%
21%202321%
20242023
— 26362
—
—1,364
2631,426
20242023(452,593)(644,206)
25%(113,148)(161,052)
(7,285)16,74735,05534,60012162(110,846)(111,915)
180,501204,34915,07616,536789735—1,364
2631,426
6.
2024123120237.
123120242023
(440,633)(631,263)
20242023
1,690,8501,687,470
202420231231
2024202312312024202312318.
20242023352,898276,778—31,261(1,896)(401)
351,002307,638
2021
20242023345,906248,9425,09658,696
351,002307,638
20242023
4011321,495268—
1,896401
20241231
352,8980.54%1,896
20231231
276,7780.14%401
9.
20242023111,795124,20713,45710,4322,99019912167
128,363134,905
10.
20241231202512220251241,126,000
5.825.576.42
( www.hkexnews.hk )( www.innocarepharma.com )20241231
2025430
ADADC
ALLAMLAQP4 IgG4
ASH
BBBCRT
BBioDuro Inc.
BiogenBiogen Inc.BIIB
BTDBTKBTK
CD20BCD20MS4A1
BCDCCDENMPA
C1
CLLCNSL
99692015113
2020
CSU
DAR
DLBCLB
DLT
EULARFGFR
FL
GMP
20199
IBDICP-022
iDMCIL-2-2IL-5-5IL-12-12IL-23-23IND
IRCITKTITPiwNHLJAK
2020323
MCLB
C3
MSMZL
NDANMOSD
NMPA
NRDLNTRKFGFR(FGFR)
TRK
PD
PK
PNPPMS
2020311
R/Rr/rR-CHOP
RICE
264,648,2172022921
SC
0.000002
SHP2RAS
SLESLLSPMSSRISLE
T
TTBNKTDCCTTRK
TYK22UC
FDAFDA
VivoVivo Opportunity Fund, L.PVivo Capital VIII,
LLCWM
2025327